舒心口服液联合贝尼地平治疗冠心病心绞痛的临床研究

Clinical study on Shuxin Oral Liquid combined with benidipine in treatment of coronary heart disease angina pectoris

目的 探讨舒心口服液联合盐酸贝尼地平治疗冠心病心绞痛的临床疗效。方法 选取2020年5月—2022年5月在郑州市第七人民医院治疗的122例冠心病心绞痛患者,按照随机数字表法分为对照组(61例)和治疗组(61例)。对照组患者口服盐酸贝尼地平片,2~4 mg/次,1次/d。在对照组基础上,治疗组口服舒心口服液,20 mL/次,2次/d。两组治疗5 d。观察两组患者临床疗效,比较治疗前后两组患者症状缓解时间,心绞痛发作频率,发作持续时间,视觉模拟评分法(VAS),血清因子白细胞介素-6(IL-6)、同型半胱氨酸(Hcy)、血管内皮细胞黏附因子-1(VCAM-1)和高敏C反应蛋白(hs-CRP)水平,及不良反应情况。结果 治疗后,治疗组总有效率(98.36%)明显高于对照组(83.61%,P<0.05)。治疗后,治疗组胸痛、胸闷、气短、乏力缓解时间均明显短于对照组(P<0.05)。治疗后,两组的心绞痛发作频率、发作持续时间、VAS评分,及血清因子IL-6、Hcy、VCAM-1、hs-CRP水平较治疗前均明显下降(P<0.05),且治疗组明显低于对照组(P<0.05)。治疗后,治疗组不良反应发生率为6.56%,明显低于对照组(16.39%,P<0.05)。结论 舒心口服液联合贝尼地平治疗冠心病心绞痛疗效显著,改善心绞痛症状明显,有效减低炎性反应。

Objective To investigate the efficacy of Shuxin Oral Liquid combined with benidipine in treatment of coronary heart disease angina pectoris. Methods Patient(122 cases) with coronary heart disease angina pectoris in the 7th People’s Hospital of Zhengzhou from May 2020 to May 2022 were divided into control group(61 cases) and treatment group(61 cases) according to random number table method. Patient in the control group was po administered with Benidipine Hydrochloride Tablets, 2 — 4 mg/time, once daily. Patient in the treatment group were po administered with Shuxin Oral Liquid on the basis of the control group, 20 mL/time, twice daily. Patient in two groups were treated for 5 d. After treatment, the clinical evaluation was evaluated, and the relief time of symptom,angina attack frequency, attack duration, VAS score, the levels of serum inflammatory factor IL-6, Hcy, VCAM-1 and hs-CRP, and adverse reaction in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group(98.36%) was significantly higher than that of the control group(83.61%, P < 0.05). After treatment, the relief time of chest pain, chest tightness, shortness of breath and fatigue in the treatment group was significantly shorter than that in the control group(P < 0.05). After treatment, the frequency and duration of angina pectoris attack, VAS score, and the levels of serum factors IL-6, Hcy,VCAM-1, and hs-CRP in two groups were significantly lower than those before treatment(P < 0.05), and these indexes in the treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the incidence of adverse reactions in the treatment group was 6.56%, significantly lower than that in the control group(16.39%, P<0.05). Conclusion Shuxin Oral Liquid combined with benidipine has remarkable curative effect in treatment of coronary heart disease angina pectoris, obvious improvement of angina pectoris symptoms and effective reduction of inflammatory reaction.